A two-year strategic research collaboration and licence agreement has been formed between Karolinska Institute spin out, Pelago Bioscience, and Vertex Pharmaceuticals that will focus on the CETSA method.
Partnership
As part of this collaboration agreement, the companies will work together to develop further assay expertise in CETSA formats and to generate benchmarking data to determine the value of implementing CETSA across Vertex’s drug discovery platform.
CETSA — Cellular Thermal Shift Assay — has become increasingly popular over the course of the last five years as a tool for use throughout the pre-clinical drug discovery pathway.
“We are delighted to be entering into this collaborative agreement with Vertex. Acceptance of the CETSA method has increased dramatically since it’s invention in 2013, but there are still so many applications left to pursue,” stated CEO of Pelago Bioscience, Michael Dabrowski. “This collaboration will allow us to explore the value of CETSA in screening, translation and safety pharmacology in collaboration with the scientists at Vertex.”
Jeremy Baryza, Senior Director of Chemical Biology at Vertex added: “CETSA is an important technology that could enable the discovery of new molecular modes of action and potentially help bring transformative medicines to patients more quickly. We are excited about working in collaboration with the scientists at Pelago”